National Bank of Canada’s Intellia Therapeutics NTLA Stock Holding History

National Bank of Canada’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$141	Buy	+11	New	+$140	﹤0.01%	2816
2024 Q3	–	Sell	-1,000	Closed	-$22.4K	–	2957
2024 Q2	$22.4K	Buy	1,000 +500	+100%	+$11.9K	﹤0.01%	1933
2024 Q1	$12.2K	Buy	500 +475	+1,900%	+$13.2K	﹤0.01%	2129
2023 Q4	$770	Hold	25	–	–	﹤0.01%	2564
2023 Q3	$728	Buy	25 +10	+67%	+$388	﹤0.01%	2622
2023 Q2	$611	Hold	15	–	–	﹤0.01%	2601
2023 Q1	$559	Hold	15	–	–	﹤0.01%	2582
2022 Q4	$523	Sell	15 -685	-98%	-$32.6K	﹤0.01%	2643
2022 Q3	$39K	Buy	+700	New	+$43.4K	﹤0.01%	1777
2022 Q2	–	Sell	-239	Closed	-$17K	–	2923
2022 Q1	$17K	Sell	239 -50	-17%	-$4.24K	﹤0.01%	2232
2021 Q4	$34K	Buy	+289	New	+$36.2K	﹤0.01%	1999

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada's NTLA Position: Q1 2026 in Review

National Bank of Canada opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 11 shares worth $141. The stake represents ﹤0.01% of the portfolio and ranks #2816 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in NTLA as recently as Q2 2024.

National Bank of Canada first reported a position in NTLA in Q4 2021 and has held it in 11 quarters since. The position peaked at $39K in Q3 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

National Bank of Canada held 11 shares of Intellia Therapeutics worth $141 as of Q1 2026.
Intellia Therapeutics was a new National Bank of Canada position in Q1 2026.
Intellia Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2816 holding.
National Bank of Canada first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 11 quarters since.
National Bank of Canada's Intellia Therapeutics position peaked at $39K in Q3 2022.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.